Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 2 Date: 08 Jun 2023
Reviewer's report:
Although the Title may appear appealing interesting for audience  who mostly go through the
abstract of the study .I have certain reservations which are enumerated below
1. The basic concept of the study where a SC bio similar(CT-P13) is being compared to originator
IV or SC VDZ. Abstract does not mention the point pertaining to bio similar anywhere which
might be misleading to readers.
2. The numbers are too small in SC bio similar group as compared to VDZ and also Pharma
sponsored  additional data was added to biosimilar group, which is still unpublished. As per my
understanding 2-3 RCTS with generally comparative numbers in each group would be ideal for
comparative Analysis
3. The comparison lacks numbers and has very heterogenous population (TNFi exposure) which
limits drawing such simplified conclusions as projected by authors
Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 2 Date: 08 Jun 2023
Reviewer's report:
Although the Title may appear appealing interesting for audience  who mostly go through the
abstract of the study .I have certain reservations which are enumerated below
1. The basic concept of the study where a SC bio similar(CT-P13) is being compared to originator
IV or SC VDZ. Abstract does not mention the point pertaining to bio similar anywhere which
might be misleading to readers.
2. The numbers are too small in SC bio similar group as compared to VDZ and also Pharma
sponsored  additional data was added to biosimilar group, which is still unpublished. As per my
understanding 2-3 RCTS with generally comparative numbers in each group would be ideal for
comparative Analysis
3. The comparison lacks numbers and has very heterogenous population (TNFi exposure) which
limits drawing such simplified conclusions as projected by authors
Please review this paper.
user
Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 2 Date: 08 Jun 2023
Reviewer's report:
Although the Title may appear appealing interesting for audience  who mostly go through the
abstract of the study .I have certain reservations which are enumerated below
1. The basic concept of the study where a SC bio similar(CT-P13) is being compared to originator
IV or SC VDZ. Abstract does not mention the point pertaining to bio similar anywhere which
might be misleading to readers.
2. The numbers are too small in SC bio similar group as compared to VDZ and also Pharma
sponsored  additional data was added to biosimilar group, which is still unpublished. As per my
understanding 2-3 RCTS with generally comparative numbers in each group would be ideal for
comparative Analysis
3. The comparison lacks numbers and has very heterogenous population (TNFi exposure) which
limits drawing such simplified conclusions as projected by authors
assistant